Third-party payers will be more than happy to pay for a short course of treatment that increases the likelihood of attaining an SVR and thereby eliminating future costs of the disease entirely. This will be one of the easiest treatment decisions the payers will ever have to make, IMO.
Market Data 
Markets 
AI
